Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.31 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560871 | 0.77 | ORAI1 (0.33) | TSHRORAI1ORAI2ORAI3 | |
| SCHEMBL1463955 | 0.74 | GPR3 (0.34) | TSHRMAOAMAOBDRD2DRD1 | |
| SCHEMBL18065143 | 0.68 | TSHR (0.42) | TSHRORAI1ORAI2ORAI3MAOA | |
| SCHEMBL3494049 | 0.65 | TSHR (0.50) | TSHRORAI1ORAI2ORAI3MAOA | |
| SCHEMBL11777743 | 0.64 | TSHR (0.41) | TSHRORAI1ORAI2ORAI3MAOA | |
| SCHEMBL7346113 | 0.63 | CA12 (0.40) | TSHR | |
| SCHEMBL19820978 | 0.62 | GPR3 (0.52) | TSHRORAI1ORAI2ORAI3MAOA | |
| SCHEMBL4166748 | 0.59 | TSHR (0.56) | TSHRORAI1ORAI2ORAI3MAOA | |
| SCHEMBL862127 | 0.59 | TSHR (0.56) | TSHRORAI1ORAI2ORAI3MAOA | |
| SCHEMBL862128 | 0.59 | TSHR (0.56) | TSHRORAI1ORAI2ORAI3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | TSHR 3339/4885ORAI1 806/4885ORAI2 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.